POLYMED
531768Intimation On Rescheduling Of Investor/Analyst Meet.
Enclosed
Poly Medicure Ltd, commonly known as Polymed, is a leading Indian manufacturer and exporter of medical devices and consumables primarily serving the healthcare and hospital sectors. Founded in 1995 and headquartered in New Delhi, the company develops a broad portfolio of over 150 products including IV cannulas, infusion therapy equipment, renal care products, diagnostics, and critical care disposables. Polymed operates modern manufacturing facilities spread across India, China, Italy, Egypt, and the United States, with R&D centers focused on product innovation and regulatory compliance.
Intimation On Rescheduling Of Investor/Analyst Meet.
Enclosed
Intimation For The Schedule Of Investors/Analysts Call/Meet.
Enclosed
Investors Call Scheduled To Be Held On 20 August, 2026 Is Cancelled - Updates On Call
Enclosed
Intimation For The Schedule Of Investors/Analysts Call/Meet.
Enclosed
Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of the news paper publication
Analyst Investor Meet Call Transcript
Enclosed
Annual Report 2025-26
Enclosed
Record Date/Cut-Off Date For The Dividend Purpose
Enclosed
Announcement under Regulation 30 (LODR)-Dividend Updates
Record Date/ Book Closure Date
Book Closure For The Purpose Of Record Date For The Purpose Of Dividend
Enclosed
Intimation Of Dispatch Of Letter To Shareholder Whose Email Address Are Not Registered With Company And Depository
Enclosed
Business Responsibility and Sustainability Reporting (BRSR)
Enclosed
31ST Annual General Meeting To Be Held On September 05Th, 2026
Enclosed
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Enclosed
Statement Of Deviation & Variation For The Quarter Ended 30Th June, 2026
enclosed
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
The company submitted the Monitoring Agency Report for the Quarter ended 30th June, 2026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
ENCLOSED
Announcement under Regulation 30 (LODR)-Investor Presentation
ENCLOSED
Announcement under Regulation 30 (LODR)-Change in Management
The Company informed about the Resignation of Mr. Ravi Prakash the Deputy Company Secretary of the Company w.e.f. close of business hours on 10th August, 2026.
The Company Granted The 1476 ESOP Options To The Employees Under The ESOP Scheme, 2020.
ENCLOSED
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Company allotted the 1975 Equity Shares under ESOP Scheme, 2020.
Standalone & Consolidated Unaudited Financial Results For The Quarter Ended 30Th June, 2026
ENCLOSED
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. 07Th August, 2026
ENCLOSED
Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E. 07Th August, 2026
ENCLOSED
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation for the Investers/Analyst Call for the Financial Results of First quarter ended on 30th June, 2026.
Poly Medicure Ltd
About
Poly Medicure Ltd, commonly known as Polymed, is a leading Indian manufacturer and exporter of medical devices and consumables primarily serving the healthcare and hospital sectors. Founded in 1995 and headquartered in New Delhi, the company develops a broad portfolio of over 150 products including IV cannulas, infusion therapy equipment, renal care products, diagnostics, and critical care disposables. Polymed operates modern manufacturing facilities spread across India, China, Italy, Egypt, and the United States, with R&D centers focused on product innovation and regulatory compliance.
The company has established a strong presence in both domestic and international markets, exporting to over 110 countries worldwide. With certifications such as CE marking and US FDA approvals for several products, Poly Medicure emphasizes quality assurance, regulatory adherence, and sustainability in its operations. Its global footprint and partnerships with major healthcare distributors reinforce its reputation as a preferred supplier in the medical devices sector.
Business Model & Strategy
Poly Medicure Ltd generates revenue primarily through the design, manufacturing, and distribution of single-use medical devices, targeting hospitals, clinics, and institutional buyers globally. The company leverages large-scale production facilities, backward integration for critical components, and continuous R&D investments to maintain product differentiation and cost efficiencies. With a diverse product mix and wide geographical reach, Poly Medicure reduces risk and capitalizes on growing healthcare infrastructure demand.
Growth strategies include expanding product portfolios—especially in high-value critical care and diagnostics—entry into new international markets, and building long-term contracts with both government and private healthcare providers. The company also emphasizes sustainable practices, digital transformation, and increasing automation to drive operational excellence and scalability.
Management Overview
14 MembersMr.DEVENDRA RAJ MEHTA
Non-Executive - Non Independent Director-ChairpersonMr.HIMANSHU BAID
Executive Director-MDMr.RISHI BAID
Executive DirectorMr.JUGAL KISHORE BAID
Non-Executive - Non Independent DirectorMr.ALESSANDRO BALBONI
Non-Executive - Non Independent DirectorMr.AMIT KHOSLA
Non-Executive - Independent DirectorMrs.SONAL MATTOO
Non-Executive - Independent DirectorMr.AMBRISH MITHAL
Non-Executive - Independent DirectorMr.VIMAL BHANDARI
Non-Executive - Independent DirectorMr.VISHAL GUPTA
Non-Executive - Independent DirectorMr.VISHALBAID
Executive DirectorMr.Pankaj Kumar Gupta
Executive DirectorMr.Naresh Vijayvargiya
Chief Financial OfficerAvinashChandra
Company Secretary & Compliance OfficerAwards & Recognition
6 Awards- Gold Award for Best Export Performance in Medical Devices (EEPC India, 2023)
- Featured in Forbes Asia 'Best Under A Billion' list (2023)
- Recipient of the India Medical Devices Company of the Year Award (Assochem, 2023)
- Great Place to Work Certification (2024)
- Recognized among Top 3 Indian MedTech Exporters (Pharmexcil, 2024)
- ESG rating improvement by multiple agencies (2024)
Market Information
Company Timeline
30+ Years of Excellence | 9 Major Milestones
Poly Medicure Ltd founded in New Delhi, India
Established first overseas subsidiary in China
Listed on BSE and NSE
Commissioned new automated manufacturing plant in Haryana, India
Acquired Plan 1 Health S.R.L., Italy to expand operations in Europe
Entered US market with FDA clearances for select products
Launched advanced diagnostics and renal care product lines
Commissioned new manufacturing facility in Neemrana, Rajasthan
Strengthened ESG reporting and received Great Place to Work Certification
The Next Evolution
Contact Information
Registered Office
232 B, 3rd Floor, Okhla Industrial Estate, Phase-III
Tel: 011-47317000 / 33550700 / 26321838 / 81 / 89 / 93 / 99,
Fax: 011-26481894 / 26481839,
Email: cs@polymedicare.com; investorcare@polymedicure.com; polymed@vsnl.com
Website: polymedicure.com
Corporate Actions
16| Purpose | Ex Date | Record Date | BC Start | BC End |
|---|---|---|---|---|
Final Dividend ₹3.50 per share | 28 Aug 2026 Friday | 29 Aug 2026 Saturday | - | - |
Final Dividend ₹3.50 per share | 18 Sep 2025 Thursday | 18 Sep 2025 Thursday | - | - |
Final Dividend ₹3 per share | 19 Sep 2024 Thursday | - | 20 Sep 2024 Friday | 26 Sep 2024 Thursday |
Final Dividend ₹3 per share | 21 Sep 2023 Thursday | - | 22 Sep 2023 Friday | 28 Sep 2023 Thursday |
Final Dividend ₹2.50 per share | 16 Sep 2022 Friday | - | 20 Sep 2022 Tuesday | 26 Sep 2022 Monday |
Dividend ₹2.50 per share | 16 Sep 2021 Thursday | - | 18 Sep 2021 Saturday | 24 Sep 2021 Friday |
Interim Dividend ₹2 per share | 27 Feb 2020 Thursday | 29 Feb 2020 Saturday | - | - |
Dividend ₹2 per share | 13 Sep 2019 Friday | - | 17 Sep 2019 Tuesday | 23 Sep 2019 Monday |
Final Dividend ₹2 per share | 18 Sep 2018 Tuesday | - | 20 Sep 2018 Thursday | 26 Sep 2018 Wednesday |
Dividend ₹0.50 per share | 20 Sep 2017 Wednesday | - | 22 Sep 2017 Friday | 28 Sep 2017 Thursday |
Bonus issue 1:1 | 24 Mar 2017 Friday | 28 Mar 2017 Tuesday | - | - |
Interim Dividend ₹1 per share | 15 Feb 2017 Wednesday | 16 Feb 2017 Thursday | - | - |
Interim Dividend ₹1 per share | 11 Nov 2016 Friday | 15 Nov 2016 Tuesday | - | - |
Dividend ₹0.50 per share | 19 Sep 2016 Monday | - | 21 Sep 2016 Wednesday | 27 Sep 2016 Tuesday |
Interim Dividend ₹2.50 per share | 17 Mar 2016 Thursday | 18 Mar 2016 Friday | - | - |
Dividend ₹2.50 per share | 18 Sep 2015 Friday | - | 22 Sep 2015 Tuesday | 28 Sep 2015 Monday |
₹17,738 Cr.
₹1,755
₹2,145 / 1,182
56.29
₹310.7
5.63
₹31.09
₹5.00
0.4 %
Manage Ratio
FINANCIALS
| Annual Results | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | - | - | - | 629 | 706 | 805 | 961 | 1,151 | 1,435 | 1,759 | 1,995 | 2,109 |
| Expenses | - | - | - | 530 | 582 | 628 | 768 | 916 | 1,093 | 1,312 | 1,567 | 1,686 |
| Profit | - | - | - | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 321 | 313 |
| Tax | - | - | - | 35 | 30 | 44 | 49 | 58 | 86 | 114 | 107 | 109 |
| EPS | - | - | - | 7 | 11 | 15 | 15 | 19 | 27 | 34 | 32 | 8.49 |
| Ratios | - |
Cash Flow
Consolidated Figures in Rs. Crores
| Annual Balance Sheet | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | - | - | - | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,919 | - |
| Equity And Liabilities | - | - | - | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,919 | - |
Shareholding Pattern
Numbers in Percentages
| Quarterly SHP Announcement Date | Mar 2016 12 Apr '16 | Mar 2017 31 Mar '17 | Mar 2018 31 Mar '18 | Mar 2019 17 Apr '19 | Mar 2020 08 May '20 | Mar 2021 19 Apr '21 | Mar 2022 15 Apr '22 | Mar 2023 19 Apr '23 | Mar 2024 16 Apr '24 | Mar 2025 18 Apr '25 | Mar 2026 02 May '26 | - |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Goverments | - | - | - | - | - | - | - | - | - | - | - | - |
| Promoter And Promoter Group | - | - | - | 48.75% | 48.76% | 44.88% | 44.66% | 53.31% | 53.15% | 62.44% | 62.42% | - |
| Non Institutions | - | - | - | 46.17% | 48.16% | 40.00% | 36.94% | 26.80% | 27.26% | 14.15% | 16.08% | - |
| FII | - | - | - | - | - | - | - | 16.21% | 12.38% | 11.46% | 5.91% | - |
| DII | - | - | - | - | - | - | - | 3.68% | 7.22% | 11.96% | 15.59% | - |
| Total | - | - | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - |
Poly Medicure Ltd
Poly Medicure Ltd
Poly Medicure Ltd, commonly known as Polymed, is a leading Indian manufacturer and exporter of medical devices and consumables primarily serving the healthcare and hospital sectors. Founded in 1995 and headquartered in New Delhi, the company develops a broad portfolio of over 150 products including IV cannulas, infusion therapy equipment, renal care products, diagnostics, and critical care disposables. Polymed operates modern manufacturing facilities spread across India, China, Italy, Egypt, and the United States, with R&D centers focused on product innovation and regulatory compliance.
The company has established a strong presence in both domestic and international markets, exporting to over 110 countries worldwide. With certifications such as CE marking and US FDA approvals for several products, Poly Medicure emphasizes quality assurance, regulatory adherence, and sustainability in its operations. Its global footprint and partnerships with major healthcare distributors reinforce its reputation as a preferred supplier in the medical devices sector.
Poly Medicure Ltd generates revenue primarily through the design, manufacturing, and distribution of single-use medical devices, targeting hospitals, clinics, and institutional buyers globally. The company leverages large-scale production facilities, backward integration for critical components, and continuous R&D investments to maintain product differentiation and cost efficiencies. With a diverse product mix and wide geographical reach, Poly Medicure reduces risk and capitalizes on growing healthcare infrastructure demand.
Growth strategies include expanding product portfolios—especially in high-value critical care and diagnostics—entry into new international markets, and building long-term contracts with both government and private healthcare providers. The company also emphasizes sustainable practices, digital transformation, and increasing automation to drive operational excellence and scalability.
Gold Award for Best Export Performance in Medical Devices (EEPC India, 2023)
Featured in Forbes Asia 'Best Under A Billion' list (2023)
Recipient of the India Medical Devices Company of the Year Award (Assochem, 2023)
Great Place to Work Certification (2024)
Recognized among Top 3 Indian MedTech Exporters (Pharmexcil, 2024)
ESG rating improvement by multiple agencies (2024)
Poly Medicure Ltd founded in New Delhi, India
Established first overseas subsidiary in China
Listed on BSE and NSE
Commissioned new automated manufacturing plant in Haryana, India
Acquired Plan 1 Health S.R.L., Italy to expand operations in Europe
Entered US market with FDA clearances for select products
Launched advanced diagnostics and renal care product lines
Commissioned new manufacturing facility in Neemrana, Rajasthan
Strengthened ESG reporting and received Great Place to Work Certification
Peer Comparison
| S.No. | Company Name | CMP (₹) | Market Cap (₹ Cr) | Div Yld (%) | NP Qtr (₹ Cr) | Qtr Profit Var (%) | Sales Qtr (₹ Cr) | Qtr Sales Var (%) | ROCE (%) | ROE (%) | Book Value (₹) | EPS TTM (₹) | TTMPE Ratio (₹) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon
Heatmap View
Premium Feature| Company | CMP (₹) | MCap (₹ Cr) | EPS TTM (₹) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Financial Ratios
Premium Feature| Company Name | P/E (TTM) | EPS (₹) | D/E | NPM | GPM | ROE (%) | ROCE (%) | P/B | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Not Found Data | |||||||||||||
Coming Soon